Home › NDC Lookup › RxCUI directory › RxCUI 2610436

20 ML betibeglogene autotemcel 20000000 CELLS/ML Injection [Zynteglo] — RxCUI 2610436

RxNorm drug concept · Semantic branded drug
RxCUI 2610436 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2610436
Official name20 ML betibeglogene autotemcel 20000000 CELLS/ML Injection [Zynteglo]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known as20 ML Zynteglo 20000000 CELLS/ML Injection; zynteglo 20 ML Injection
FDA products mapped1
Package NDCs mapped1
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Betibeglogene autotemcel Injection: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Yes — Zynteglo is designed as a one-time treatment. It permanently modifies your own stem cells so they produce working hemoglobin going forward. That said, the full process takes...
  • There's quite a bit of preparation involved. First, you'll receive medications to push stem cells out of your bone marrow into your bloodstream, then they're collected through a pr...
  • What happens to my body before I actually get the infusion?
  • The most common side effects — many of which are actually related to the chemotherapy conditioning rather than the infusion itself — include mouth sores, fever, low white blood cel...
📖 Read our full Betibeglogene autotemcel Injection guide →

🕸️ Concept Web — How 20 ML betibeglogene autotemcel 20000000 CELLS/ML... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept 20 ML betibeglogene autotemcel 20000000 CELLS/ML Injection [Zynteglo] RxCUI 2610436

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Betibeglogene autotemcel 2610349
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Zynteglo 2610355
  3. Dose forms 6

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Betibeglogene autotemcel Injection 2610352
    • Betibeglogene autotemcel Injectable Product 2610351
    • Betibeglogene autotemcel Injection [Zynteglo] 2610358
    • Zynteglo Injectable Product 2610357
    • Injection 1649574
    • Injectable Product 1151126
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 11 of 11 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Brand-Name Concepts

  • Betibeglogene autotemcel 20000000 CELLS/ML [Zynteglo] SBDC · 2610433
  • Betibeglogene autotemcel Injection [Zynteglo] SBDF · 2610358
  • Zynteglo Injectable Product SBDG · 2610357
  • Zynteglo BN · 2610355

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 2610436 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
73554-3111-01 1 SUSPENSION in 1 BAG (73554-3111-1) Zynteglo Genetix Biotherapeutics Inc. 2022-08-17
Observed labelers: Genetix Biotherapeutics Inc. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.